Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

On April 16, 2010, the U. S. Food and Drug Administration (FDA) approved erlotinib tablets (Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC) whose disease had not progressed after four cycles of platinum-ba...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Cohen, Martin H., Johnson, John R., Chattopadhyay, Somesh, Tang, Shenghui, Justice, Robert, Sridhara, Rajeshwari, Pazdur, Richard
Формат: Artigo
Язык:Inglês
Опубликовано: AlphaMed Press 2010
Предметы:
Regulatory Issues: FDA
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227916/
https://ncbi.nlm.nih.gov/pubmed/21148614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0257
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы